<SEC-DOCUMENT>0000950103-20-001096.txt : 20200127
<SEC-HEADER>0000950103-20-001096.hdr.sgml : 20200127
<ACCEPTANCE-DATETIME>20200127164111
ACCESSION NUMBER:		0000950103-20-001096
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200127
FILED AS OF DATE:		20200127
DATE AS OF CHANGE:		20200127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zai Lab Ltd
		CENTRAL INDEX KEY:			0001704292
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38205
		FILM NUMBER:		20550074

	BUSINESS ADDRESS:	
		STREET 1:		4560 JINKE ROAD
		STREET 2:		BLDG. 1, 4F, PUDONG
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862161632588

	MAIL ADDRESS:	
		STREET 1:		4560 JINKE ROAD
		STREET 2:		BLDG. 1, 4F, PUDONG
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp119732_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center">&nbsp;<B>SECURITIES AND
EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.75pt 0pt 177.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.75pt 0pt 177.35pt; text-align: center"><B>REPORT OF FOREIGN
PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.75pt 0pt 177.35pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.75pt 0pt 177.35pt; text-align: center"><B>PURSUANT TO RULE
13A-16 OR 15D-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.75pt 0pt 177.35pt; text-align: center">&nbsp;<B>OF THE SECURITIES
EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.85pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 157.5pt 0pt 153pt; text-align: center; text-indent: -0.05pt"><B>For
the month of January 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 157.5pt 0pt 153pt; text-align: center; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 135pt; text-align: center; text-indent: -0.05pt"><B>Commission
Filing Number: 001-38205</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 135pt; text-align: center; text-indent: -0.05pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.35pt 0pt 106.9pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 21.5pt Times New Roman, Times, Serif; margin: 0pt 106.35pt 0pt 106.9pt; text-align: center"><B>ZAI LAB LIMITED</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.35pt 0pt 106.9pt; text-align: center"><B>(Translation of registrant&rsquo;s
name into English)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.35pt 0pt 106.9pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.85pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.85pt; text-align: center"><B>4560 Jinke Road,
Bldg. 1, 4F, Pudong, Shanghai, China 201210</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"><B>(Address of principal
executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F &#9746; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>




<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.4pt 0pt 106.9pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 87%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press release issued January 27, 2020.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 38pt 0pt 5.3pt; text-align: center; text-indent: 22.05pt"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 38pt 0pt 5.3pt; text-align: center; text-indent: 22.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 38pt 0pt 5.3pt; text-indent: 22.05pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 38pt 0pt 5.3pt; text-indent: 22.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ZAI LAB LIMITED</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Billy Cho</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Billy Cho</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Date: January 27, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp119732_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.85pt 0pt 5.3pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.85pt 0pt 5.3pt; text-align: right">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 95px; width: 338px"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Zai Lab Announces Closing of Public Offering
of American Depositary Shares and Full Exercise of Greenshoe Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SHANGHAI, China, and SAN FRANCISCO, Jan. 27, 2020 (GLOBE NEWSWIRE)
-- Zai Lab Limited (&ldquo;Zai Lab&rdquo; or the &ldquo;Company&rdquo;) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial
stage biopharmaceutical company, today announced the closing of its previously-announced underwritten public offering of 5,500,000
American depositary shares (&ldquo;ADSs&rdquo;), each representing one ordinary share of the Company (the &ldquo;Primary ADS Offering&rdquo;),
at a price of US$47.50 per ADS. In addition, QM11 Limited, a shareholder of the Company, offered 500,000 ADSs of the Company (the
&ldquo;Secondary ADS Offering&rdquo; and together with the Primary ADS Offering, the &ldquo;Offering&rdquo;) at the same price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zai Lab and QM11 Limited had also granted the underwriters a
30-day option to purchase up to an additional 800,000 and 100,000 ADSs, respectively at the public offering price, less underwriting
discounts and commissions. The underwriters fully exercised their option to purchase these additional ADSs. Given the full exercise
of the option, QM11 Limited now owns approximately 12.15% of the Company&rsquo;s share capital immediately following this Offering.
The Offering closed on January 27, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The gross proceeds to Zai Lab from this Offering, before deducting
underwriting discounts and commissions and other offering expenses, were approximately US$299.3 million. Zai Lab did not receive
any proceeds from the sale of ADSs by QM11 Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. Morgan, Citigroup, Goldman Sachs &amp; Co. LLC and SVB
Leerink acted as joint book-running managers, and Guggenheim Securities acted as lead manager for the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ADSs were offered pursuant to a shelf registration statement
on Form F-3ASR, which became automatically effective upon filing with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on March 29, 2019 and was subsequently amended and became automatically effective upon filing with the SEC on January 21, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering was made only by means of a prospectus supplement
and an accompanying prospectus included in Form-3ASR. The registration statement on Form F-3ASR and the prospectus supplement are
available at the SEC&rsquo;s website at: http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus
may be obtained from: (i) J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com, (ii) Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146, (iii) Goldman Sachs
&amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, by facsimile
at (212) 902-9316 or by email at prospectus-ny@ny.email.gs.com or (iv) SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525 ex. 6132 or by email at syndicate@svbleerink.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release does not constitute an offer to sell or the
solicitation of an offer to buy ADSs or any other securities, nor shall there be any sale of ADSs in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws
of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">About Zai Lab</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zai Lab (NASDAQ:ZLAB) is a China and U.S.-based innovative commercial
stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to
patients in China and around the world. The company&rsquo;s experienced team has secured partnerships with leading global biopharma
companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China&rsquo;s pharmaceutical
market and addressing unmet medical needs. Zai Lab&rsquo;s vision is to become a fully integrated biopharmaceutical company, discovering,
developing, manufacturing and commercializing its partners&rsquo; and its own products in order to impact human health worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zai Lab Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release includes certain disclosures which contain
&ldquo;forward-looking statements.&rdquo; You can identify forward-looking statements because they contain words such as &ldquo;anticipate&rdquo;
and &ldquo;expected.&rdquo; Forward-looking statements are based on Zai Lab&rsquo;s current expectations and assumptions. Because
forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances
that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical
fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially
from those in the forward-looking statements are set forth in Zai Lab&rsquo;s Annual Report on Form 20-F for the fiscal year ended
December 31, 2018 and its other filings with the U.S. Securities and Exchange Commission. Zai Lab undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as
may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information, please contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ZAI LAB CONTACTS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zai Lab</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Billy Cho, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+86 137 6151 2501</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">billy.cho@zailaboratory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media: Ryo Imai / Robert Flamm, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Burns McClellan, on behalf of Zai Lab</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212-213-0006 ext. 315 / 364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">rimai@burnsmc.com / rflamm@burnsmc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors: Pete Rahmer / Mike Zanoni</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Endurance Advisors, on behalf of Zai Lab</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">415-515-9763 / 610-442-8570</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !D 5\# 2(  A$! Q$!_\0
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M  *3_&ES+N7["K_(_N9JT5E?\)3HO_08L/\ P*3_ !IT'B'2[F39#J5G,_\
M=CG5C^AHYEW$Z51*[B_N-!SU_*O$?VGI"N@Z*N6VM=,2 < _(?S->VLZD8!!
MXSUKQ']I_P#Y >@GM]J;G_MF:PQ+_=2/<X?_ .1I1OW?Y,] ^$LAD^'?A\LY
M<_9$RQZFNQS7 _"S4+;3OA=H,]U<Q6L"VJ[I9G"*.3U)K:/Q$\*J<'Q%I>?^
MOR/_ !K2$ER*[Z(X<91J3Q=;V<6US2V7F=)FC-<U_P +&\*?]#'I7_@9'_C1
M_P +&\*'_F8]*_\  R/_ !J^:/<Y?JM?_GV_N9TU%<Y'\0_"SD!?$>DY/ 'V
MV($_^/5N07$5U"LL,B2QL,JZ'((^M--/9F<Z52GK.+7JB>BBBF9!1110 AZ5
M\K_M"J1\0GX)_P!&CY ]O_K&OJ@YP<=:\K^('P23Q[KQU.34VLLQI&(U@#XV
MY[Y'K7-B(2J0Y8GTG#^-H8#&>UQ#M&S6S?5=CY?S[TF1ZBO?O^&7(?\ H8)/
M_ 3_ .SH'[+T"98^()< ?PVF3_Z&:\SZK5[?B?I7^LN5_P#/W_R67^1X$01G
M(/UH]/<@5U7Q(\(6'@?6DTRUU%M1N%7=,6BV;"1P/K]*Y1O7\,_Y]C7+*+A)
MQ9]#0K0Q%*-:G\+5UOM\TC2\/:!=>)]:L]+LP#/<OM#$9"#/+_0?J.E?9/A?
MP]9>$]%MM,L8A%#"H'099L<L3W).237F/[/G@$Z3I+Z]=QD75\H$",!^ZB'I
M]>OTKT[Q3K\/A;0+W4Y\^7;1%PHZL>P_,@5[&&I>SASRZ_D?D_$>8RQ^+6#H
M:QB[>LMOPV1Q'Q@^*\?@FW^PZ<4DUJ= 5WCY85_O-Z^PKYHU76[_ %V=I]0O
M;B\E8_?G<NP'X\#J>!P!^-+K6L76OZM=ZC>-ON+F0R,V>@/1?P''%4>.Y 'J
M>!7FUJTJLKWT/T#*,II99144KS>[\^R\A>"3MP=OWL'./KZ?C1CG !)_V>3^
M5=]X&^#.N>-(ENB5TS3B>+B?)9N?X4_B'N3@UZ,/V8K#[/M;6+EI,?>\I=F?
M7;FG##U)*Z0L3GV7X2?LZE3WNMDW;[CP&UO+G3ITGMYI+:>,Y22-BK+^/4'Z
M<5N^*_'-[XRTW2(=0'FW=@CQFX)RTJDK@GU.!R>YK=\??!C5_ L#7B,NH:8I
MPTT*;63W*YX_#(]Z\^7YL8Y![^M9R4Z?N,[Z$\)C^3%46I-7L^JTM;NM]A?U
MKZ"_9=_Y!_B'_KXC_P#037SY7T'^R[_R#_$/_7Q'_P"@FML+_%7S/&XG_P"1
M74]8_P#I2%_:=_Y FA_]?4G_ * *^?/X37T'^T[_ ,@30_\ KZD_] %?/G\)
MHQG\5APS_P BRG_V]_Z4SV[]F3(U/7R!DB)./7FM3]IN9H]&T.)78))<2%E'
M1L*,?CD]>U9G[,?_ "$]>_ZY)_.M#]I\_P"@>'_3SYO_ $%:Z8NV%?\ 74^?
MK*_%$;_U[AZ/\*YVG^'OA]W=G?[&@)8Y)P .:Z^N+^$.?^%<^'\]?L@_F:[2
MO1A\*]#X#')1Q55+I*7YL****LX@HHHH S=7TT:KIUW9-(\*7,31F2,X9<C&
M0?6O&F_9<MF8D>(IL$Y^:U!/XG?S7NA90,DX'O7+:I\4?"FCSM!=:]9I,O#(
MC[ROL=N<&L:D*<M9GL9=C,PPW-# MZ[V5_T9YI_PRU;?]##)_P" @_\ BZ;_
M ,,LQ?\ 0PO_ . 8_P#BZ]"_X71X+S_R'HO^_4G_ ,33?^%U^"O^@['_ -^9
M?_B:Y_98?R^\]U9CQ#VG_P""U_\ (GG[?LM0X./$39][,8_]#JK=_LOW$$#O
M9>(%DG RJ2VNQ2?J&./K@UZ5_P +K\%?]!V/_OS+_P#$U=T?XG>%_$%^MC8:
MS!-=O]V%E9&;V&X#)]J:I8=Z*WWBEFW$%*+E/F26]X*WS]T\-^&'CC7/"GCR
M/P_J]Y<7-L\_V)X+ARPADYP4Y/!.!VZUUG[3ZD:)H/0C[6X]_P#5FN \7$1?
M'5B1C&JP$L/]]:]!_:?8-H>AX.,7;\?\ -<UW[*<7T/?G3@\VP6*C&SJ1N[=
M^7_@FCX=\"VWQ!^#/AS3+NXEMXTC696B(Z@,.0>HY-9J?LOV"9 URXV]@+=.
M/QS7=_!S_DF_A_\ Z]1_,UVU=BHPG%.2Z(^2K9MCL%B*U'#U.6//+2R[^:/$
M/^&8K#_H.W/_ 'X7_&C_ (9BL/\ H.W/_?A?\:]OHI_5J78S_P!8<T_Y_?A'
M_(\,E_9BM C&'7KA9B, M I'\Z\^T:^UKX.^/H],>\8VRSJ)8$<F&6)C]_;Q
MAOI7UB1GKR*^7/V@&V?%8$=1;VY_\>;_  KGKTHTHJ<-'<^BR/,<3FM:>$QL
MN>#B]TO+;0^HXSN0'U%/J&#/D1YZ[1_*IJ]$_.]M HHHH ***:S8&>M "DX!
M/6N&^*GCZ/P/X8DGC*G4IODM8VP<MQEB/0?X5V%W=Q6MK++*P2)%+,Q.  .]
M?(/Q.\;2^.?$\UT"?L,7[NUC/9 <9^I/-<N(J^RAINSZ7(,L_M+%7FOW<-7Y
M]E\_R.6N[R>_NIKJYE,UQ,Q>1SR78GGZ<\8KN?@[X!'CCQ&QNHV.F66'N,\!
MV_YYY'<YYZ8'3FN&MK::\N(8+>(S3RN(XD49+L?3^=?8?PV\%1>!O#%MIZ@&
M<@RW#CG?*W4_TKS,-3]K.[V1^B\0YE_9N%]G2=IRT5NB[_+9'2VT"6<:QH@2
M-0%1%Z* . /2O'/VFM<DMM TO3(WV"[E:60>JICC\V4_A7M3=J^<_P!IR;=K
MNBQ$ [+>1AGH,LO^%>GB7:D['YUPY2C5S2DI=+O[DVOQ/&#T';V]!Z5Z%\%?
M ]OXS\2RMJ$+3Z=9QB22/G$C$X4$_F<=QFO/CR2?6OH;]FBV1/#FK7 SODNE
M1OHJ<?\ H1KRL-!3J),_4,_Q,\)E]2=-VD[)/M=K]#V6VA2"W6.-%1$&U448
M4 =AZ58 (')R::F-M/KWS\*O?4KW5K'>0203(LD4@VLC#((KY-^,W@F'P3XK
M\NRB,6G72&6) <A#D9'/09/Y5]=5X5^T_ ITO1+@#,@N'BR?0KG\N*X\5!.F
MWV/K>&,54HYA&DG[L[IKY73_  /GZOH/]EW_ )!_B'_KXC_]!-?/IX)KZ"_9
M=_Y!_B'_ *^(_P#T$UYV%_BKYGW_ !/_ ,BNIZQ_]*0O[3O_ "!-#_Z^I/\
MT 5\^?PFOH/]IW_D":'_ -?4G_H KY\_A-&,_BL.&?\ D64_^WO_ $IGMW[,
MG&IZ]_URC_G6C^U"<:9H#\D">4?^.I6?^S&,ZKKH_P"F4?\ .NL_:$\.7.J^
M$(+NWC\UK&?S64<D1D?,?KTKJIKFPK^?YGS6)JQI<31E-V6B^^-CIOA)C_A7
M.@$?-_HP&1]379@Y^M?-GPO^.EOX1\.0:3JMG<W4-N,0W%MABP))Y!( Z^M=
MNO[2_A?'_(/U@#WAB_\ CE=%.O3Y%=GA8_),P^MU6J3:<F]/-W/7:*\C_P"&
MEO#'_0/UC_OQ'_\ '*0_M,>&!UL-7'UAB'_M2K]O3_F.'^Q,Q_Y\L]=HKR'_
M (:9\+?\^&K_ /?J'_X[5K2OVB/#&K:A!:+!J-LTSB-9+B*,)D^X<TU7IO3F
M)EDN8Q3DZ,K(Q/VB_&^HZ!%8:58SO;K>([SM&<,R @;<]5Y[BL_P9^SQ::GH
MMK>:WJ5UY]P@E,%L5 0$9 )(//.*M?M*^%[B_L['6X(C)#:(\5P5.2B'!#8[
MC(JAX'_:%ATS1;:QUNQN))+=%C6XLPKEP.,D%A@^XS7'-P]LU6VZ'U6&CBO[
M(I2RNW-=\]K<V_GY'3_\,T>&O^?[5,?]=8O_ (W2_P##-'AK_G\U/_O]'_\
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ME#_\=KIIUZ?(KL^<S'(\P>+JRA2;3;::\]3U^BO(O^&F?"__ $#]7_[]1?\
MQVD_X:8\,?\ 0/U<?]LHO_CM7[>G_,>?_8>9?\^)?<>M-(%(&,D]*^7?V@,M
M\4P /^7>W^I.7XKT2;]I?PXR-Y6G:H\@&55DB /Y2'%>2M=ZA\6OB;;S"W*M
M/+&?+SQ%"C Y_+/U-<V(JPJ14(.[N?3</Y=BL!B*F*Q4.2,8O<^KVO8;.T22
MXD6&,*,NY  J%-?T^6*61;N%HXL;W612%ST)P>]0:[I5MJFBW-I=PK<0&/.Q
M^02HR#^>*\472[:P_9SU*]@MXXKF>/,TD0P7VS #OSW%=<YN+M;H?)X/!4\7
M%-R:;G&.R^UU_!GO1U"%;<SLZB #<92PVXQG.<XQ2PWD=S$LD1WQN,JRG((]
M17A>H7%Q+X6;X>"1_MEK<R([X);["BF5&^A!5!]*]%^$3A_AMX;;))-FF&SG
M.1_]:G"ISRM8>*R[ZK0]LY7O*RTWBTW&7SL=S3&.U2?2G$X%<?\ $GQS#X'\
M,W%ZQ!NI 8K9/[TA'!^@ZUI)J*<F>;1HSQ%6-&FKRD[(\M^/OQ(D\\^&M.F"
MJ%S?M&02?1,]O4X^E>&@?* J\XQQT'^ [XI]U<S7US+<SR&6>5VDD?IN8]_I
MCM70_#_PA/XU\46^GQ*3 K![B4?=1!SU]3C&/>O G*5>H?N^#PU#)L%RWLHJ
M\GW?5_Y'JG[/WPYBEB'B:_A#/NQ8!Q]T=#)CU->]JN,\YJG86,&F6D-M;1B.
M")?+1%'  [59\T>]>W3IJG%11^*9CCYYCB95Y[=%V71?Y^8]ESCVKP#]J'32
MMQH%\J_*PE@8^^4(_3<?PKWPR #H:X#XV>&V\3^!KM88O,N;,BZ0#D_+G<![
M[2PJ:\.>FTCIR/$QPN8T:D]KV?ST_4^3?Y>M>Y?LT>((XYM7T>1\.X2YB4]#
MCAL>_*\5X:I)4?W<<5H^']<N_#6LV>I63%+BW?>,G"L,<J?4<GBO$HU/934F
M?LV:8+^T,)/#K=K3U6J/N&,90'.<^E25QO@+XD:3XYTY)+25(KL#]Y:.WSH?
MZBNM\P8_^O7T$9*2NC\#K4:F'FZ=6+37<<&QD<#\:^=OVE]?6XU?2]'0C=;H
MT\@SP&;A1^0/->M>/_B-IO@/2GGNY0;M@1#:@Y=V[<>GO7R5KFM77B+5KK4;
MYB]S<R&1\G[N>BCV&%_+WKAQ=5*/(MV?<<*Y;4J8CZ[-6C&]O-M%&OH+]EW_
M )!_B'_KXC_]!-?/G/?D^M?0?[+O_(/\0_\ 7Q'_ .@FN+"_Q5\SZ_B?_D5U
M/6/_ *4A?VG?^0)H?_7U)_Z *^?/X37T'^T[_P @30_^OJ3_ - %?/G\)HQG
M\5APS_R+*?\ V]_Z4SV_]F#_ )"VN_\ 7*/^=?03QB1"I ((P01P17S[^S!_
MR%M=_P"N4?\ .OH:O2PO\)?/\S\]XF_Y&E3Y?DCAK_X->#=3NI+BXT.$RN26
M,4DD8)^BL!4'_"B? W_0#'_@5/\ _%UZ!16[IP>KBCQXYECH+EC7FE_BE_F>
M??\ "B? W_0"'_@5/_\ %TH^ _@@=-%P/^OJ;_XNO0**7LJ?\J&\TQ[T>(G_
M .!2_P SS_\ X43X(_Z _P#Y,S?_ !=26?P3\&V%W'=0Z.HFC8,C-/*P!'0X
M+D$UWE%"I07V5]Q+S'&M6=>?_@3_ ,RM+;)/&\<BJ\;#!5@""/0@UQEU\%/!
M=Y,TTFAQ^8Q))CFEC!_!6&*[RBKE&,OB5SFH8FOAFW0J.-^S:_(\_P#^%$^!
M_P#H"#_P+G_^+H_X45X'_P"@(/\ P+G_ /BZ] HJ/94_Y4=7]IX__G_/_P "
ME_F>?_\ "B? _P#T!?\ R;G_ /BZ/^%$^"%.X:(-W_7U.?\ V>O0**/94_Y4
M']I8Y[UY_P#@3_S,K1?#VG^';1+73;2&SME.1'"FT9]??\:TW4.,'I3J*T2M
ML>?*4IMRD[MG%:G\'_"6LW3W-UHL!F<Y9XF>/)]PK 533X$^"5ZZ-D?]?4X_
M]GKT&BH=.#U<5]QVQS#&P5HUI)?XG_F<#_PHKP1_T!/_ ";G_P#BZ/\ A17@
MC_H"?^3<_P#\77?44O94_P"5%?VECO\ G_/_ ,"E_F>?GX%>"",?V*,>GVJ?
M_P"+KH/#G@C1?"2.FD:?%8J_+%/F8_\  CD_AFN@HJE"$7=(SJXW%5X\E6K*
M2[.3:_,@DA$T;(_*L"&'J#VK'/@O2&\._P!A&RC.DXP;7G:?FW>N>O/6M^BJ
M:3W.6,YP^%M=?GW]3#?PGI4NJ3ZDUG&U[/#]GDFQ@M'TVGV[5<TG1K;0]-M[
M"RB6WM+=!'%$HX11VK0HIA*I.2Y92;7KVV^XI7U]%I]G+<W+K'#$A>1ST51U
MKY%^)7C^X\>:VTYPEC 6CMH0",+G.\^I/K7M_P ;;;Q-KFEPZ-H6G2W-O.=]
MS,C!<J/X.37BO_"G?&>#G0ICGOYD?_Q72O-Q4IS]R*T/T7ABA@\-!XO$5(J;
MV3:32^;W?Y>IQ=6K#5+W279[&\GLBXVM]GD*$CZCG\JZG_A3GC+_ * <W_?R
M/_XJC_A3GC+_ * <W_?R/_XJO.5.HMDS[R6/P,E:56#7^*/^9B_\)GX@R3_;
MNI@GTO9?_BJ/^$S\0_\ 0>U/_P #9?\ XJMK_A3GC+_H!S?]_(__ (JC_A3G
MC+_H!S?]_(__ (JKM5\S'ZQEK^W3^^!B'QGX@QQKVI@^OVR0^_K[5],? ^[N
M-4^'%G/>3R7DSR3*9+AR[$;R,9/;VKP+_A3OC+D_V%,<#H)$YY'N?4U]#?!G
M0K[P]X#M+#4K<VUU'+*S1,<G!<D5V855%/WKVL?(\3UL'/!*.'E!OF7PN-]G
MV/&/C)\*3X0NVU73(VDTB=OWBYX@<D]3CA>>I^E>7<>FX8_B7!'^%?=-[:0:
MA;2VUS&L\$J;7B=00P]"*^=_'W[/E_IT\MUX;7[=9D[OL;-MDC]0I_B'MU]Z
M6(PS3YZ:*R+B*$X+#8V5I+:3V:[/S\SR&"XFM9DE@E>&5.5>-MI'^/XUOI\1
M_%"0>5_;^H,F,?Z]A_*LJ^T+4=+=DO+"YMG!P5EA*$5!;V5S>2^7;VTUQ)_=
MBC9R/^^<UYZYUM<^ZG##UUSS2EYM)_B)=7MQ>7#3W,TEQ.Q):65B['\34:H2
MN0I51[<=N_?J.*]%\$_ [7O$ES%->0OI6G9RTDZD2./14(!!]S^5=;\5_A1>
MFVT"P\-Z6]Q;6L<AD(*@LYV?,QXR3@GL*V5"I*+FU_F>3/.<%2Q,,+&:UW=U
M:*6OIJU:QX77T'^R[_R#_$/_ %\1_P#H)KR__A3GC+_H!S?]_(__ (JO9/@%
MX4U?PGIVMQZM9/9R33HT:N0=P"G)K7#0FJB;1Y7$6+PU;+:D*=2+=XZ)I]5V
M,S]IW_D":'_U]2?^@"OGS^$U],?'WPGJ_BK2]'BTFR:]>*X=I%1@"H*8!YKQ
M@_!SQG@_\2*;_OY&?_9J>*A*=5V0N',9AJ670A4J1B[RT;2ZONSOOV8/^0MK
MO_7*/^=?0U>)_ /P5KGA34M7?5M/>R69$$99E.[!YZ5[97?ADXTDGYGPG$56
MG6S*I.G)-::IWZ+L%%%%=1\T%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!$(Q4FT>_YT44"[AM'O^=&T>_YT44##:/?\Z-H
M]_SHHH ;L##!S^="(%S_ "HHIDIZBD;NM-:,>IY]Z**10GE+LP1D#UYI!"J@
M8&/I11320>0HC QUI/+ ''?C%%%(5EL2[1C'/YU&(P,?SQ113&]KB[1S[4$9
M[G\Z**!/00+MZ?A4M%%#)B[A1112+"BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
